AIM ImmunoTech (AIM) vs Soligenix (SNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Soligenix is the larger company by market cap ($7.6 million vs $7.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | SNGX |
|---|---|---|
| Share price | $0.1809 | $0.3501 |
| Market cap | $7.22M | $7.62M |
| 1-day change | -0.22% | +0.99% |
| EPS (TTM) | $-2.98 | $-0.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $1.80 |
| 52-week low | $0.17 | $0.28 |
| Distance from 52-week high | -93.52% | -80.55% |
| Analyst consensus | none | none |
| Avg. price target upside | +2249.36% | +294.17% |
| Average volume | 4.70M | 249.87K |
| Shares outstanding | 39.89M | 21.77M |
| Employees | 19 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About Soligenix
SNGX stock →Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
AIM vs SNGX FAQ
Which is bigger, AIM ImmunoTech or Soligenix?
Soligenix (SNGX) is larger, with a market capitalization of $7.62M compared with $7.22M for AIM ImmunoTech (AIM).
Are AIM ImmunoTech and Soligenix in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AIM ImmunoTech and Biotechnology: Pharmaceutical Preparations for Soligenix.